CXCR4-directed [68Ga]Ga-PentixaFor PET/CT vs AVS performance in a diagnoStic randomized Trial Ultimately comparing hypertenSion outcome in primary aldosteronism
- Conditions
- Aldosterone overproductionPrimary aldosteronis1000135310014710
- Registration Number
- NL-OMON49887
- Lead Sponsor
- Radboud Universitair Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 228
- The patient has a diagnosis of primary aldosteronism, confirmed by an
elevated aldosterone/renin ratio (ARR) and an intravenous salt-loading test
(according to the Endocrine Society guidelines)(1)
- Patients who fall in the *grey area* according to the Endocrine Society
guidelines (1), will be discussed with all site investigators before inclusion
to reach consensus on the diagnosis before inclusion.
- Age over 18 years at time of consent
- Signed informed consent
- Refusal by the patients to undergo AVS, [68Ga]Ga-PentixaFor PET/CT, CT, or
adrenalectomy
- Suspicion of familial hyperaldosteronism type 1, type 2, type 3 or type 4
- Suspicion of adrenocortical carcinoma
- Severe comorbidity potentially interfering with treatment or health-related
quality of life
- Requirement of medication interfering with the study protocol
- Any medical condition present that in the opinion of the investigator will
affect patients* clinical status.
- Pregnancy or lactation
• Estimated glomerular filtration rate (eGFR) kleiner dan 40 ml/min/1.73m²
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method